Last reviewed · How we verify
RVP-001
At a glance
| Generic name | RVP-001 |
|---|---|
| Also known as | MnPyC3A, Mn-PyC3A, mangaverate |
| Sponsor | Reveal Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent (PHASE2)
- First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |